Mantle Cell Lymphoma Pipeline

DelveInsight’s, “Mantle Cell Lymphoma Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Mantle Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

Mantle Cell Lymphoma Understanding

Mantle Cell Lymphoma Overview

Mantle cell lymphoma (MCL) is a rare and aggressive form of B-cell non-Hodgkin lymphoma, primarily distinguished by the characteristic t (11; 14) chromosomal translocation, leading to the overexpression of cyclin D1. This genetic alteration drives the uncontrolled proliferation of B-cells. MCL presents with a range of morphological variants, which can complicate its diagnosis, although some cases remain straightforward. Clinically, MCL tends to follow an aggressive course, but a less common, indolent leukemia variant has also been observed. Despite its rarity, understanding MCL's distinct genetic and clinical features is crucial for accurate diagnosis and treatment. The aggressive form of MCL often involves rapid progression, leading to widespread lymphadenopathy, extranodal involvement, and poor prognosis without timely intervention. In contrast, the indolent variant of MCL may present with a more chronic course, sometimes resembling chronic lymphocytic leukemia, and often has a better response to treatment.

 

Mantle cell lymphoma (MCL) is primarily driven by a reciprocal chromosomal translocation, t (11; 14) (q13; q32), which results in the overexpression of cyclin D1 (CCND1) through its juxtaposition with the immunoglobulin heavy chain gene locus. This leads to dysregulated cell cycle progression, chromosomal instability, and epigenetic changes that contribute to tumor cell proliferation. While most MCL cases are associated with this translocation, rare instances may involve CCND2 or CCND3 translocations. MCL can be classified into two molecular subtypes based on the cell of origin. The classical or aggressive MCL arises from naive B cells, with limited or absent immunoglobulin gene mutations and the expression of SOX11, a transcription factor that impedes B cell differentiation. The indolent variant, on the other hand, originates from antigen-experienced B cells that have undergone somatic hypermutation, are typically SOX11-negative, and are genetically stable.

Mantle cell lymphoma (MCL) presents with a variety of symptoms, many of which are common physical issues that individuals may not immediately recognize as signs of cancer. As a result, many patients are diagnosed with widespread disease. Among the key indicators are B symptoms, which are typical of B-cell lymphoma. These include drenching night sweats, persistent fevers that don't respond to over-the-counter medications, and unexplained weight loss (at least 10% of body weight over six months without intentional changes to diet or exercise). Additional symptoms may include nausea, vomiting, or diarrhea; swollen lymph nodes in areas like the neck, armpits, or groin; heartburn, abdominal pain, or bloating; discomfort or fullness from enlarged tonsils, liver (hepatomegaly), or spleen; lower back pain or pressure, sometimes radiating down the legs; and fatigue.

 

Mantle cell lymphoma (MCL) remains an incurable disease, with median overall survival ranging from 1.8 to 9.4 years depending on the disease's aggressiveness. Treatment decisions are based on factors like disease aggressiveness, patient performance status, age, and the mantle cell international prognostic index (MIPI) score. Indolent MCL may be monitored with a "watch and wait" approach if the patient has favorable characteristics, such as low Ki-67 and no B symptoms. For aggressive MCL, chemotherapy regimens like R-CHOP, R-DHAP, and hyper-CVAD are commonly used, with stem cell transplantation considered for eligible patients. In relapsed or refractory cases, more intensive treatments, including targeted therapies like ibrutinib, acalabrutinib, and venetoclax, as well as chimeric antigen receptor T-cell (CAR-T) therapy, have shown promise. While these therapies improve outcomes, MCL still presents significant treatment challenges.

 

"Mantle Cell Lymphoma Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mantle Cell Lymphoma pipeline landscape is provided which includes the disease overview and Mantle Cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Mantle Cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mantle Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Unlock insights into Mantle Cell Lymphoma market trends, epidemiology, and forecasts through 2034 to drive strategic decisions and growth opportunities.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Mantle Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Mantle Cell Lymphoma.

Mantle Cell Lymphoma Emerging Drugs Chapters

This segment of the Mantle Cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mantle Cell Lymphoma Emerging Drugs

• Glofitamab: Roche

Glofitamab (Columvi) is a CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi is designed with a novel 2:1 structural format. This T-cell-engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. Columvi is being investigated as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma. Glofitamab has also been granted Orphan Drug Designation by the US FDA for the treatment of Mantle Cell Lymphoma. Currently, the drug is in Phase III stage of its development for the treatment of Mantle Cell Lymphoma.

 

• Zilovertamab vedotin: Merck Sharp & Dohme LLC

Zilovertamab vedotin is an Antibody-Drug Conjugate (ADC) composed of a monoclonal antibody against the Tumor-Associated Antigen (TAA) Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of zilovertamab vedotin targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the ROR1-expressing cancer cells, through an as of yet unknown mechanism of action. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival. Currently, the drug is in Phase II stage of its development for the treatment of Mantle Cell Lymphoma.

 

• ONM-501: OncoNano Medicine, Inc.

ONM-501 is a dual-activating STING (STimulator of INterferon Genes) agonist delivered to the tumor microenvironment to produce dendritic cell maturation, prime cytotoxic T cells, and induce a strong adaptive immune response.  Preclinical data has shown evidence that ONM-501 prolongs STING activation with a low potential for systemic side effects, including cytokine storms. In murine models, ONM-501 has demonstrated antitumor efficacy, and when combined with checkpoint inhibition, produces a synergistic tumor cell death. Currently, the drug is in Phase I stage of its development for the treatment of Mantle Cell Lymphoma.

 

• MB 105: March Biosciences

MB-105, selectively targets CD5, a widely expressed antigen both in normal and malignant T-cells. CD5 is a cell surface marker that is commonly expressed in normal T-cells, thymocytes, and a small subset of B-cells. It is widely expressed in T-cell malignancies. It is further highly expressed in T-cell acute lymphoblastic leukemia and certain B-cell malignancies such as Mantle Cell Lymphoma (MCL) and Chronic Leukocytic Leukemia (CLL). The specific engineering of MB-105 CAR enables preservation of normal T-cells, while maintaining cytotoxicity against CD5+ tumor cells, avoiding risk of severe immunodeficiency. CAR T-cell expansion promotes early terminal T-cell differentiation, resulting in potent but short-lived effector cells incapable of driving patient responses. . Currently, the drug is in Preclinical stage of its development for the treatment of Mantle Cell Lymphoma.

Further product details are provided in the report……..

Unlock insights into Mantle Cell Lymphoma epidemiology trends through 2034, empowering strategic decisions with data-driven forecasts and market intelligence today.

Mantle Cell Lymphoma Therapeutic Assessment

This segment of the report provides insights about the different Mantle Cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Mantle Cell Lymphoma

There are approx. 20+ key companies which are developing the therapies for Mantle Cell Lymphoma. The companies which have their Mantle Cell Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Roche.

Mantle Cell Lymphoma Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Mantle Cell Lymphoma Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Mantle Cell Lymphoma Clinical Trial Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Mantle Cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Mantle Cell Lymphoma Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mantle Cell Lymphoma drugs.

Mantle Cell Lymphoma Report Insights

• Mantle Cell Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Mantle Cell Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered In The Mantle Cell Lymphoma Pipeline Report : 

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Mantle Cell Lymphoma drugs?
• How many Mantle Cell Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mantle Cell Lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mantle Cell Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mantle Cell Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Roche
• Merck Sharp & Dohme LLC
• OncoNano Medicine, Inc.
• March Biosciences
• Wellington Zhaotai Therapies Limited
• Regeneron Pharmaceuticals
• Nurix Therapeutics, Inc.
• Cellectar Biosciences, Inc.
• Adicet Therapeutics
• Oncternal Therapeutics, Inc
• AstraZeneca
• Atara Biotherapeutics
• Accutar Biotechnology Inc
• AbbVie
• Galapagos NV

Key Products

• Glofitamab
• Zilovertamab vedotin
• ONM-501
• MB 105
• WZTL002-1
• Odronextamab
• NX-2127
• Iopofosine I 131
• ADI-001
• Cirmtuzumab
• AZD5492
• ATA3219
• AC676
• ABBV-291
• GLPG5101